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Background: Lipid metabolism is altered in subjects with liver steatosis. FAS is a key enzyme in de novo lipogenesis
and both FAS gene expression and enzymatic activity are primarily regulated by metabolic signals in the liver.
Lipoprotein lipase (LPL), the rate-limiting enzyme for the hydrolysis of core triglycerides, plays a pivotal role in lipid
metabolism. This study aims to investigate if circulating levels of FAS and LPL could be clinically associated with
liver steatosis.
Methods: In this work, we present data obtained from a subsample of 94 subjects with liver steatosis enrolled by
NUTRIEPA study, a nutritional trial in subjects with liver steatosis. Serum levels of FAS protein and LPL activity were
evaluated by ELISA test and by a fluorescent method, respectively. The diagnosis and the degree of liver steatosis
were based on laboratory and ecographic measurements. Statistical methods included Kruskal-Wallis analysis
of variance and Wilcoxon signed-rank test, where appropriate. The χ2 test has been performed to analyse
categorical variables.
Results: The subjects with severe steatosis had significantly higher serum levels of FAS protein and LPL activity
compared to subjects with mild and moderate liver steatosis. Moreover, a positive trend in serum levels of
FAS expression from lower to higher degree of steatosis was also detected.
Conclusions: We describe a relationship between human liver steatosis and elevated levels of circulating
lipogenic enzymes. Increased serum levels of FAS expression and LPL activity could be considered a marker of
severe liver steatosis.
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Liver steatosis may be considered the consequence of an
increased influx of free fatty acids or a decreased export
of lipids through very low density lipoprotein (VLDL),
less fatty acid oxidation or increased de novo lipogenesis
in the liver [1]. Liver steatosis is frequent in patients
with metabolic syndrome and accumulating evidences
suggest that lipid metabolism is as important to diabetes
as carbohydrate metabolism [2].
Insulin is the most lipogenic hormone [2,3] and it is
an important regulator of fatty acid synthase (FAS). FAS
is a cytosolic multi-enzyme that functions normally in* Correspondence: gabriella.caruso@irccsdebellis.it
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FAS is a key enzyme in de novo lipogenesis [4,5] and
both FAS gene expression and enzymatic activity are pri-
marily regulated by metabolic signals in the liver [3].
Despite being an intracellular protein, it may be released
into the extracellular space and may be a biomarker of
metabolically demanding human diseases [6]. Increased
FAS levels have been detected in serum of patients with
different clinical stages of breast cancer [7]. Recently, a
significant association between circulating levels of FAS
and HER2-overexpressing metastatic breast cancer
patients has been described [8]. Moreover, our previous
study showed that serum levels of FAS in colorectal can-
cer patients were associated with tumor stage, suggesting
that serum FAS detection can be used for distinguishing
the patients with metastatic colorectal cancer [9].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in patients with chronic hepatitis viral infections and cir-
culating FAS concentration correlated with the degree of
liver steatosis [10].
Enhanced FAS expression is a poor prognostic factor
in patients with breast, prostate, and ovarian cancer,
generating an intriguing paradigm that cancers with high
expression of FAS have a growth and/or survival advan-
tage [11,12]. FAS expression appears also to play an im-
portant role in the growth and neoplastic transformation
of colonic mucosa [12,13]. Our previous study demon-
strated that FAS activity levels, as well as the expression
of its mRNA are up-regulated in colorectal cancer tis-
sues compared with “normal” surrounding mucosa [13].
Lipoprotein lipase is the rate-limiting enzyme for the
hydrolysis of core triglycerides in chylomicrons and
VLDL [14]. LPL plays a pivotal role in lipid metabolism
and changes in LPL expression could affect both the rate
of fat accumulation and the metabolism of triglyceride-
rich lipoproteins [15]. In patients with resectable non-
small cell lung cancer, high levels of LPL activity have
been detected in cancer tissue [16]. Moreover, increased
LPL activity in non-small cell lung cancer tissue predicts
shorter patient survival, independent of standard prog-
nostic factors. Recently, we have demonstrated a signifi-
cant reduction in both LPL and FAS gene expression
and activity levels in peritumoral adipose tissue of colo-
rectal cancer patients [17], demonstrating that a tumor-
induced impairment in the formation and lipid storing
capacity of adipose tissue occurs in patients with colo-
rectal cancer.
A recent study shows that an up-regulation of LPL
evoked an insulin resistant state in hepatocytes in mice
and finally developed into hepatic steatosis [18].
On the basis of these evidences, the measurement of
circulating FAS and LPL could be useful in the manage-
ment of metabolic diseases, as steatosis. This study aims
to explore serum levels of FAS protein and LPL activity
in patients with steatosis in order to assess a possible
clinical association between levels of enzyme expression
and degree of liver steatosis.
Methods
Patients
This work is part of NUTRIEPA study, a nutritional trial
enrolling consecutive subjects with liver steatosis, diag-
nosed by abdominal ultrasound.
In this report, we present data obtained from a sub-
sample of 94 subjects. All subjects underwent a
complete medical examination including weight and
height measurements. Body mass index (BMI) was cal-
culated as weight in kilograms divided by the square of
the height in meters (kg/m2). Participants were fasted
for 12 h prior to examination. Blood samples taken fromthe subjects by venous puncture were collected in tubes
containing a serum separator gel. Aliquotes of blood
serum were stored at −80°C until assayed or shipped to
the central laboratory for routine analyses. All the ana-
lyses were performed within 6 months.
In order to obtain a semiquantitative evaluation of fat
in the liver, we used a system scoring [19,20]. Degree of
fatty infiltration of the liver was graded according to
ultrasonographic appearance of liver echotexture, hep-
atic echo penetration and clarity of hepatic blood ves-
sels, liver diaphragm differentiation in echo amplitude.
Each criterion was assigned a score indicating the level
of fatty liver infiltration. A score of 2 indicated a definite
positive (++) fatty liver infiltration for that criterion. A
score of 1 was assigned for a probable positive (+) find-
ing based on the criterion. When a negative (−) evalu-
ation for fatty liver was made from a criterion, a score of
0 was assigned to the criterion. The sum of the scores
for the three criteria was considered to be an indicator
of severity of fatty infiltration. Thus, the fatty liver indi-
cator ranged from 0 to 6, with mild fat infiltration for a
total score 1–2; moderate for a total score of 2–4, severe
indicated by a total score ≥ 5.
Moreover, a control group of subjects without liver
steatosis was included. In this group, the liver steatosis
was excluded by ultrasonographic and laboratory
evaluation.
The study had institutional approval and all patients
gave informed consent to participate in the study.
FAS analysis
FAS analysis was performed by a commercially available
ELISA kit, FAS-detect ELISA (FASgen, IMMTECH, Bal-
timore, MA, USA) according to the manufacturer's
recommendations.
Briefly, sera were incubated in a 96-well capture plate
on a plate shaker for 90 min at room temperature. The
plate was then washed five times with wash buffer. FAS
enzyme conjugate was added and the plate was incu-
bated for 60 min, and the wash was repeated. Serum
FAS levels were visualized by color change upon
addition of tetramethyl-benzidine substrate followed by
addition of substrate stop solution. Absorbance values
were read at 450 nm using a spectrophotometer. FAS
concentrations were determined by interpolation from
the standard curve. Intra-and inter-assays coefficients of
variation (CV) were less than 8%, and the detection limit
was 2.0 ng/ml.
LPL analysis
LPL enzymatic activity was evaluated on serum samples
by a fluorescent method (LPL activity Kit, Roar Biomed-
ical, New York, NY). Aliquotes of 100 μl of serum were
incubated with 100 μl of pre-diluited substrate emulsion
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mendations. The hydrolyzed triglycerides formed were
measured at 370 nm excitation and 450 nm emission.
The fluorescence intensity values of samples were com-
pared with the fluorescence intensity values of standard
curve applied on the same plate together with samples
in each run. LPL activity was expressed as picomoles of
hydrolyzed substrate per minute per ml of serum (pmol/
min/ml). All measurements were made in duplicate and
intra-and inter-assays coefficients of variation (CV) were
less than 5%.
Laboratory measurements
In order to estimate the HOMA index, serum levels of
glucose and insulin were measured by an automated sys-
tem (Uni Cel Integrated Workstations DxC 660i, Beckman
Coulter, Fullerton, California, USA) using chemiolumines-
cent immunometric methods. Samples over calibration
range were automatically reanalyzed according to con-
structor's instructions.
Statistical analysis
The significance of the differences among the groups
was evaluated by Kruskal-Wallis analysis of variance,
Wilcoxon signed-rank or Mann–Whitney test, where ap-
propriate, and χ2 test for trend. All data were expressed
as mean ± SD. Differences were considered significant at
P < 0.05. The χ2 test has been performed to analyse cat-
egorical variables.
Results
Liver steatosis was diagnosed and its grade was assessed
with the findings of liver ultrasound scan performed by
the same radiologist. We found 33 subjects with mild
liver steatosis, 38 with moderate and 23 with severe
steatosis.
Table 1 shows descriptive analysis of studied variables
in controls and subjects stratified for degree of liver
steatosis.
Serum levels of FAS protein and LPL activity among
the groups were significantly different. The subjects with
steatosis showed circulating levels of FAS and LPL sig-
nificantly higher than controls. Moreover, stratifying for
score of steatosis, the subjects with severe steatosis had
significantly higher serum levels of FAS protein and LPL
activity compared to subjects with mild and moderate
liver steatosis.
In addition, a positive and statistically significant trend
in serum FAS concentration from lower to higher degree
of steatosis was also detected (Table 1).
The values of BMI and HOMA index were statistically
different among the groups of subjects and the test for
trend was also significant (Table 1).No difference among the groups was detected in rela-
tion to sex and age (Table 1).Discussion
In this study we describe a relationship between human
liver steatosis and elevated levels of circulating lipogenic
enzymes expression, such as FAS and LPL. To our
knowledge, we show for the first time, elevated levels of
LPL activity in serum from patients with severe steatosis,
suggesting that serum LPL activity measurement may
add substantial information for the evaluation of liver
impairment.
The over-expression of FAS is associated with the de-
gree of liver steatosis because of a positive trend was
detected in serum levels of FAS from lower to higher de-
gree of steatosis.
Although liver biopsies and nuclear magnetic reson-
ance imaging are the methods of choice for diagnosis of
liver steatosis, ultrasonography is currently the preferred
method for screening asymptomatic patients with sus-
pected liver injury [21]. Several studies have demon-
strated that the sensitivity, specificity and positive
predictive value of this technique to detect steatosis as
high as 80-100% [22-24]. Taking into account for the
ethical concerns, we could not perform liver biopsy of
our patients. However, in the light of clinical and labora-
tory parameters, the diagnosis of steatosis was clearly
demonstrated.
FAS and LPL are central enzymes of lipid metabolism.
FAS is believed to be a major determinant of the max-
imal hepatic capacity to generate fatty acids by de novo
lipogenesis [5]. Over-expression of FAS has been
detected in non-alcoholic fatty liver disease (NAFLD)
where increased mitochondrial oxidation of fatty acids
takes place [4]. FAS expression in steatosic hepatocytes
may be considered as a compensatory adaptation at early
stages of NAFLD.
The state of over-nutrition-induced insulin resistance
and decreased de novo lipogenesis have been demon-
strated to be associated with increased FAS in serum
[2,25]. Circulating FAS levels of obese individuals could
be considered a marker of metabolic failure in the con-
tex of over-nutrition-induced insulin resistance and
metabolic stress [25]. A recent study demonstrates
enhanced serum levels of FAS in patients with chronic
hepatitis viral infections and they correlated with the de-
gree of liver steatosis [10].
Dysfunction of LPL has been indicated in several dis-
orders including dyslipidemia and atherosclerosis [26].
Sequenzial changes in the activities of LPL and lipogenic
enzymes have been demonstrated in patients with tumor,
as well as in animal model of cancer [16,17,27,28].
Moreover, hepatic LPL deficiency seems to protect









P value^° Contrasts P value§
Sex 0.36
male (%) 12 (57.2%) 6 (18.2) 9 (23.7) 8 (34.8)
female (%) 9 (42.8%) 27 (81.8) 29 (76.3) 15 (65.2)
Age (years) 44.2±10.5 54.9±10.7 53.1±12.3 49.8±11.5 0.37
BMI (kg/m2) 25.2±4.1 32.1±3.3 31.6±4.8 34.7±5.4 0.02 Mild vs Severe
0.001* P= 0.03
Moderate vs Severe P= 0.01
HOMA index 1.3±0.9 3.2±1.5 3.5±1.9 7.03±14.0 0.04 Mild vs Severe
0.001* P= 0.018
Moderate vs Severe P= 0.07












All data expressed as percentage or M±SD; ^χ2-square test for categorical variable; °Kruskal-Wallis test for continuous variable; §Wilcoxon rank-sum
(or Mann–Whitney) test; *Test for trend.
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mice [18].
LPL generates free fatty acids that induce insulin re-
sistance in muscle and liver [29]. It has been suggested
that insulin resistance is an essential requirement for the
accumulation of hepatocellular fat [30].
In this study, high levels of FAS and LPL activity
detected in subjects with steatosis are in agreement with
the presence of insulin resistance evaluated in same sub-
jects. Moreover, the patients with severe liver steatosis
showed a value of BMI significantly higher, demonstrat-
ing that some individuals develop metabolic complica-
tions in relation to their degree of obesity.
Conclusions
FAS and LPL, intracellular proteins, appear to exit cells
during liver impairment and their presence in serum
could be considered a marker of liver steatosis.
Therefore, it is clinically important that specific biomar-
kers of metabolic changes are identified in order to assess
the efficacy of diagnosis and therapeutic treatment.
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